Semaglutide
Also known as: Ozempic, Wegovy
GLP-1 receptor agonist: slows gastric emptying, increases satiety, improves insulin sensitivity.
- Typical dose
- 250 mcg – 2.4 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 7 days
- Routes
- Subcutaneous
- Status
- FDA-approved (Ozempic for T2D, Wegovy for weight management)
Benefits
- Significant weight loss
- Blood sugar control
- Cardiovascular protection
- Reduced appetite
Dosing
A common research range for Semaglutide is 250 mcg to 2.4 mg once weekly. Titrate: 0.25mg x4wk → 0.5mg x4wk → 1.0mg → up to 2.4mg. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Semaglutide has an approximate half-life of 7 days. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.
Storage
2-8°C; room temp up to 56 days.
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Contraindications
- Personal/family history of MTC
- MEN 2 syndrome
- Pancreatitis history
Commonly stacked with
Track Semaglutide with Vial
Vial logs every Semaglutide dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Semaglutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.